Sacubitril/valsartan versus valsartan initiation in patients naive to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF.

ABSTRACT:

Aims

Whether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed.

Methods and results

This was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status. The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8.

SUBMITTER: Nouhravesh N 

PROVIDER: S-EPMC12482847 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature